The ongoing HUDSON trial evaluated the antitumor efficacy of Durvalumab in combination with T-DXd for the treatment of patients with HER-2 overexpressing (HER-2e) or HER-2-mutant (HER-2m) NSCLC. Here, ERBB2 is linked to non-small cell lung carcinoma.